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Abstract  
BACKGROUND: Myasthenia gravis (MG) is an autoimmune disease caused by the action of specific antibodies 
to the postsynaptic membrane of the neuromuscular junction, leading to impaired neuromuscular transmission. 
Patients with MG have an increased incidence of other autoimmune diseases.  
AIM: to determine the presence of other associated diseases in patients with MG. 
METHOD: A group of 127 patients with MG followed in 10 years period, in which the presence of other associated 
diseases has been analysed. 
RESULTS: The sex ratio is in favour of the female sex, the average age of the initial manifestation of the disease 
is less than 50 years, 65.4% of the patients with MG have another disease. 15.0% patients have associated 
another autoimmune disease. Thyroid disease is the most common associated with MG, rarely rheumatoid 
arthritis (RA), systemic lupus erythematosus (SLE) and other autoimmune diseases. Other diseases include 
hypertension, heart disease, diabetes, respiratory diseases, dyslipidemia. 10.2% of the patients are diagnosed 
with extrathymic tumours of various origins. 
CONCLUSION: Associated diseases are common in patients with MG, drawing attention to the possible common 
basis for their coexistence, as well as their impact on the intensity and treatment of the disease. 
 
 
 
 
 
 
 
Introduction 
 
Myasthenia gravis (MG) is an autoimmune 
disease caused by a variety of complex mechanisms 
of action of specific antibodies to the postsynaptic 
membrane, leading to impairment of the function of 
the neuromuscular junction (NMJ) and neuromuscular 
transmission.  
Cardinal clinical features are the weakness 
and fatigue of different, specific muscle groups with 
characteristic distribution, which increase with activity, 
and are improved with rest [1] [2]. 
The thymus plays a central role in the 
pathophysiology of MG due to the presence of the 
key elements of the myasthenic autoimmune 
process, such as antigen presenting cells, T and B 
cells. Approximately 80% of patients with MG have 
thymic abnormalities; up to 70% of patients have 
thymic hyperplasia, 10 - 15% of thymomas, and in 
15 – 20% thymus is normal or regressive, i.e. 
atrophic and replaced with fat tissue [3] [4] [5]. 
Current trends in the treatment of MG arise 
from the pathogenesis of the disease and provide 
satisfactory control in most patients. However, the 
course of the disease and the outcome of the 
treatment may be affected by other conditions: 
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associated autoimmune diseases (AD), diseases 
common in the general population or tumours [2] [4]. 
In some patients, these diseases occur 
before, and in others after the manifestation of MG. 
This study is aimed to assess the frequency 
and type of comorbidity in the examined group of 
patients with MG. 
 
 
Methods  
 
An observational study of 127 patients with 
MG monitored retrospectively and prospectively on 
the Neurology Clinic in 10 years period. The 
demographic characteristics of patients, the clinical 
manifestation of the disease, thymectomy, thymic 
pathology and the presence of associated diseases 
have been analysed.  
The diagnosis of MG was confirmed by 
clinical examination, by the positive response to 
Prostigmin, specific antibody testing, neuromuscular 
weakness response to repetitive nerve stimulation 
test, computed tomography (CT) on the anterior 
mediastinum. 
The severity of the disease was defined 
according to the classification of Osserman-Jankins, 
modified by Abt PL et al. (2001) [6] [7].  
Patients with MG were monitored with 
regular neurological examinations, and other 
investigations were performed depending on the 
clinical manifestation of the associated conditions.  
The diagnosis of thyroid disease is based on 
clinical features, examination, laboratory findings 
and ultrasound examination. 
The diagnosis of Rheumatoid arthritis (RA) 
and systemic lupus erythematosus (SLE) is set 
according to the Criteria of the American College of 
Rheumatology (ACR) [8] [9]. 
Statistics: Statistical analysis is made in 
statistical programs: STATISTICA 7.1; SPSS 17.0 
(Difference test, Pearson Chi-square). 
 
 
Results  
 
All 127 patients included in the study have a 
confirmed diagnosis of MG. The basic demographic 
and clinical characteristics of patients are shown in 
Table 1; average age in MG patients with or without 
associated autoimmune disease is shown in Table 2, 
and Table 3 presents the characteristics of patients 
with MG and associated disease. 
Table 1: Characteristics of the total number of patients with MG 
in the study 
Gender N % 
Female 81 63.8 
Male 46 36.2 
Age (years) N   
≥ 50  70 55.1 
< 50  57 44.9 
Age at diagnosis (years) Average N 
Female 44.5 81 
Male 56.5 46 
 n=127 48.8 127 
Age at onset (years) Average N 
Female 43.3 81 
Male 55.7 46 
N=127 47.8 127 
Comorbidity N % 
Yes 83 65.4 
No 44 44.6 
Associated autoimmune disease N % 
No 108 85 
Yes 19 15 
Hypothyroidism   % 
Yes 12 9.4 
Hyperthyroidism   
 Yes 4 3.1 
Sle    
 Yes 1 0.8 
Ra   
 Yes 2 1,6 
Vasculitis   
 Yes 1 0.8 
Thrombocytopenia   
 Yes 1 0.8 
Heart disease   
 Yes 31 24.4 
Hypertension   
 Yes 60 47,2 
Diabetes mellitus   
 Yes 18 14,2 
Dyslipidaemia   
 Yes 14 11 
Respiratory disease   
 Yes 17 13.4 
Tumors   
 Yes 13 10.2 
*SLE -systemic lupus erythematosus; *RA-rheumatoid arthritis. 
 
The sex ratio is 1.9: 1 in favour of the female 
sex, statistically significant, p = 0.0001.  
The difference in the average age at the first 
symptoms, which is higher in men, is statistically 
significant, p = 0.001564 (Table 1). 
MG with late onset (over 50 years) have 
55.1%, and with early onset (under 50) have 44.9% of 
the patients, statistically non-significant, p = 0.1040 
(Table 1). 
Majority of 83 (65.4%) patients with MG have 
another disease, p = 0.0009 (Table 1). 
Older than 50 years are 81.9%, younger than 
50 years, are 18.1 % of patients with comorbidity, p = 
0.0001, (Table 2 and 3). 
Table 2: Mean age in patients with MG with/without associated 
autoimmune disease 
Without With t-value Df P Without With Sd-without Sd- with 
47.25 51.0 -0.712645 125 0.477394 108 19 21.55329 18.58614 
 
 
A subgroup of 73 from a total of 83 (88%) 
patients with comorbidity present a generalised form 
of the disease, while 10 (12%) have an ocular form of 
the disease. 
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Table 3: Characteristics of patients with MG with associated 
disease 
Gender N=83 % 
Female 51 61.4 
Male 32 38.6 
Age (years) N   
≥ 50 68 81.9 
< 50 15 18.1 
Age at diagnosis (years) Average N 
Female 55.8 51 
Male 67.6 32 
Age at onset (years) Average N  
Female 54.8 51 
Male 66.7 32 
Associated autoimmune disease  N=19  % 
≥ 50 11 57.9 
< 50 8 42.1 
Hypothyroidism  N=12   
≥ 50 7 58.3 
< 50 5 41.7 
Hyperthyroidism   n=4   
≥ 50 2 50 
< 50 2 50 
Sle     
≥ 50 1 100 
Ra     
≥ 50 2 100 
Vasculitis      
≥ 50 1 100 
Thrombocytopenia      
≥ 50 1 100 
Heart disease  N=31   24,4% 
≥ 50 30 96.8 
< 50 1 3.2 
Hypertension  N=60   47,2% 
≥ 50 57 95 
< 50 3 5 
Diabetes mellitus N=18  14,2% 
≥ 50 17 94.4 
< 50 1 5.6 
Dyslipidaemia  N=14   11% 
≥ 50 11 78.6 
< 50 3 21.4 
Respiratory disease   n=17 13,4%  
≥ 50 17 100 
Tumors  N=13  10,2%  
≥ 50 11 84.6 
< 50 2 4 
*SLE -systemic lupus erythematosus; *RA-rheumatoid arthritis. 
 
 
Associated autoimmune diseases (AD) 
Nineteen (15.0%) patients have associated 
another AD, 11 (57.9%) are older than 50 years. (≥ 
50 years), and 8 (42.1%) are younger than 50 years. 
(˂ 50 yrs) (Table 3). In 14 (73.7 %) of them, the 
associated AD was diagnosed before MG. Fifteen 
15 (78.94 %) are women; 8 (53.3%) are younger, 
and 7 (46.7%) are older than 50 years. Men are 4 
(21.06%), and all have late-onset MG (≥ 50 years). 
Sixteen (12.6 %) have thyroid disease (Table 3).  
The generalised form of MG have 14 
patients (87.5%) (11 with hypo-, 3 with 
hyperthyroidism), and with ocular form, there are 2 
patients (one with hypo and hyperthyroidism). Two 
(1.6%) of the patients have rheumatoid arthritis (RA) 
and a generalised form of MG (Table 1). One patient 
(0.8%) is with SLE, with a generalised form of MG. 
One patient (0.8%) is with vasculitis and a generalised 
form of MG, and one (0.8%) with thrombocytopenia 
and ocular MG (Table 1). 
Patients with vasculitis and thrombocytopenia 
are considered separately from other patients with the 
confirmed associated AD. In these patients, the 
aetiology of the condition has not been confirmed with 
certainty, but according to immunological tests, the 
probability of their immunological basis is high. 
One patient has MG and two associated AD 
- RA and hypothyroidism. From the 19 patients with 
the associated AD, 15 (78.9%) were generalised, 
and 4 (21.1%) had an ocular disease. There is no 
significant association between the clinical form of 
MG and the associated AD (Table 4).  
Table 4:  Association between the clinical form of MG and 
the associated AD  
Associated autoimmune disease Pearson Chi-square p 
Hypothyroidism 0.546045 0.45994 
Hyperthyroidism 0.291224 0.58944 
SLE 0.185305 0.66685 
RA 0.375129 0.54022 
Vasculitis 0.185305 0.66685 
Thrombocytopenia 5.52734 0.01872 
  
In patients with MG and associated AD, AChR 
antibody tests were done on 6: the results were 
positive on 4 patients, from which 2 were non -
thymectomized with Graves's disease and 2 
thymectomized patients were with hypothyroidism 
(Hashimoto thyroiditis), with micro microthymoma 
B1B2, thymic hyperplasia. The other 2 patients with 
rheumatoid arthritis and hyperthyroidism (Graves's 
disease) were negative for the antiAChRat. 
 
Other associated diseases 
All patients have a generalised form of the 
disease, and most are older than 50 years (Table 1 
and 3). There is no significant association between 
severity of MG and associated disease (Table 5). 
Table 5: Association between severity of MG and other 
diseases 
Another disease Pearson chi-square P 
Hypertension 0.036403 0.84869 
Diabetes mellitus 0.797006 0.37199 
Heart disease 5.63665 0.01759 
Dyslipidaemia 0.455038 0.49995 
Respiratory disease 1.49967 0.22072 
 
 
Tumors 
Thirteen (10.2%) patients were diagnosed 
with extrathymic tumours of different origin (Table 1), 
11 (84.6%) were with late-onset MG (Table 3 and 6).  
Table 6: MG patients with extrathymic tumours 
MG/tumor N=13 
Before MG dg After MG dg 
Prostate cancer 1 Malignant melanoma  2 
Breast cancer    1 Adrenal tumour 1 
Kidney cancer 1 
 Basocellular skin cancer 1 
 Uterine tumour 2 
 Tonsil tumour 1 
 Parotid gl. tumour 1 
 Breast fibroid tumour 1 
 Brain meningioma 
  
Some patients with extrathymic tumours, also 
have associated autoimmune disease other than MG -
rheumatoid arthritis, hypothyroidism, vasculitis. 
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Thymectomy 
A group of 23, from a total of 83 patients 
(27.7%), are thymectomized (Table 7). 
Table 7. Thymus histology  
Thymus histology N = 23 
Thymic hyperplasia 15 (65.2%) 
Thymoma (3 malignant t, thymoma AB 1, thymoma B1B2 1) 5 (2.7%) 
Thymic atrophy/fatty replacement 2 (8.7%) 
Persistent thymus 1 (4.3%) 
 
From the 19 patients with the associated 
autoimmune disease, 7 (36.8%) underwent 
thymectomy; 5 (71.4%) had thymic hyperplasia, all 
women, with an average age of 32.8 years. (min 20, 
max 56), and only one had positive antiAChRat. 
In these 5 patients with thymic hyperplasia 
and associated autoimmune disease, 4 were with 
hypothyroidism, and one patient with SLE. 
Two of the operated patients with 
hypothyroidism (Hashimoto thyroiditis) had thymoma, 
and late-onset MG, average age - 64 years, one 
patient had + antiAChRat, and the other was not 
tested. 
Other patients with thymus pathology had 
hypertension, heart and respiratory diseases, 
diabetes, dyslipidemia. 
 
 
Discussion 
 
Autoimmune diseases are a heterogeneous 
group of diseases caused by loss of immune 
tolerance to their antigens in which multiple alterations 
to the immune system result in a spectrum of 
syndromes that either target specific organs or the 
whole body [10]. 
The incidence is approximately 80/100,000 
inhabitants per year, approximately 5% of the 
population is affected by one or more autoimmune 
diseases, and the prevalence is higher in women than 
men. In patients with one AD, there is a greater risk of 
developing another AD, or more. The common 
influence of the genetic, immunological, hormonal and 
environmental factors is considered to be the cause of 
these diseases [5] [10] [11] [12] [15]. 
Patients with MG have an increased 
incidence of other autoimmune diseases such as 
rheumatoid arthritis, systemic lupus erythematosus, 
Hashimoto thyroiditis, Graves' disease and pernicious 
anemia, and the frequency varies widely: from 8.7 to 
25%, 13 to 22%, while the rates of association in the 
Norwegian and Danish studies are 22.9%, i.e., 9.4% 
[13][14][15][16]. 
In MG with the associated AD, the female 
patients, with early - onset and generalised MG are 
predominant, although the other group, late-onset 
MG, exhibits an increased risk of associated AD 
compared with the general population [17]. 
Associated AD varies among different MG 
subgroups. Thymus hyperplasia is considered to be at 
greater risk for the associated AD, unlike MG with 
other than antiAChR types of antibodies (to titin, or to 
a ryanodine receptor) are associated with a lower risk 
[17]. 
Thyroid disease is the most common AD 
associated with MG, with a prevalence of 5 – 10%, 
while MG is present in 0.2% of the patients with 
diagnosed autoimmune thyroid disease [14]. 
Acute disease and the use of corticosteroids 
affect the thyroid function, but at the same time, 
corticosteroids have a positive effect due to their 
immune - regulatory function associated with the 
proliferation of AChR (acetylcholine receptors) [18] 
[19]. 
In various studies, these diseases are 
differently represented, but the most common is the 
hypothyroidism (Hashimoto thyroiditis) about 
hyperthyroidism (Graves' disease) [20] [21]. MG -
associated autoimmune thyroid disease is considered 
to have a milder form, and the ocular form has a 
special relationship with it [22]. The explanations for 
this association are: a) ocular and generalised MG are 
considered as two different diseases that may be 
associated with various other autoimmune conditions; 
b) cross - immune response to epitopes or 
autoantigens common to thyroid and eye muscles; c) 
genetic basis [23] [24]. 
The prevalence rate of coexistence of SLE 
and MG in published studies is usually around 2.6%, 
but in the study of Sthoeger Z. et al. on 78 patients, 
the rate rises to 7.7%, with greater prevalence of 
women [25] [26] [27]. 
MG is organ - specific (antibodies to AChR), 
while SLE is a systemic autoimmune disease affecting 
multiple organs, producing a wide spectrum of 
antibodies (targeted mainly to nuclear antigens and ds 
- DNA) and impaired T and B cell function [28]. 
Autoantibodies are the basis of 
immunopathogenesis for both diseases, and 
molecular mimicry, as a potential mechanism for 
initiating and/or maintaining the production of 
autoantibodies, is related to the association of MG 
and SLE. Also, there is a similarity among the 
segment of AChR for U1, the nuclear 
ribonucleoprotein that is an autoantigen marker for 
SLE, and a mixed connective tissue disease. Most of 
the antibodies in MG are targeted to a small region of 
the alpha subunit of the AChR, called the major 
immunogenic region. Various autoimmune diseases 
begin with a wide range of reactivity towards multiple 
autoantigens, and in MG, according to such structural 
similarities, the response to the main immune region 
of the acetylcholine receptor is polyreactive [28] [29]. 
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Almost equal is the number of patients where 
MG is initially diagnosed, and thymectomy has been 
performed, and the same number of patients in whom 
SLE occurs after thymectomy, which imposes the 
dilemma about the role of thymectomy [30] [31]. 
Rheumatoid arthritis occurs in 4–7% of 
patients with MG, and after thyroid autoimmune 
disease, RA is frequently present [13] [14] [17] [18] 
[25]. Patients with MG as a result of RA treated with d-
penicillamine [33] have also been described. None of 
our patients has been treated with d - penicillamine. 
Similarly, with the findings of the patients with SLE, 
RA manifestations are also less pronounced than 
those of MG. 
It has been observed that the frequency of 
heart disease or increased mortality due to heart 
disease in patients with MG is equal to the prevalence 
of the general population [34]. 
The most common are cardiac rhythm 
disorders, sympathetic destabilisation, and especially 
parasympathetic function [35]. Particular attention 
deserves patients with MG and severe cardiomyositis, 
where the heart muscle can be the target of 
autoimmune inflammation in MG (antibodies to titin, 
striated muscles, ryanodine receptors which are 
detected in thymoma and elderly patients react with 
the heart muscle) [36] [37]. 
DM prevalence among MG patients varies 
from 2 – 3 % to 20 % in different studies [18]. 
In these patients, late MG is more frequent, 
unlike those without DM. It is more frequent in men 
than women (29 vs 16 %). Patients with MG and DM 
may have positive more organ-specific antibodies 
(with DM type 1), or onset of DM during corticosteroid 
therapy (DM type 2) [38]. Doses of prednisolone 
higher than 30 mg/day increase the level of glycaemia 
in patients who already have DM, and can cause 
glucose intolerance or diabetes in previously 
normoglycaemic subjects [39]. Therefore, it is unclear 
when corticosteroid therapy directly induces DM, or 
only accelerates the manifestation of the disease. 
In most of the patients with MG, respiratory 
symptoms are manifested in the advanced stage of 
the disease, but in some patients, depending on the 
intensity of the weakness and fatigue, it can be 
acutely manifested. Chronic respiratory diseases and 
infections are the most common precipitating factor for 
severe respiratory muscle weakness [40] [41]. Thirty 
nine percentage (39%) of the patients have reduced 
vital capacity, and 19 % with severe generalised MG 
have experienced a myasthenic crisis with the need 
for assisted ventilation [34] [40]. 
A higher prevalence of dyslipidemia in MG 
was found in the general population - 60 vs 27%, even 
in patients who do not receive steroids (50%). It is 
more common in men, with late-onset MG. Treatment 
with statins preparations may cause exacerbations of 
MG [18] [42]. 
Hypertensive disease in patients with MG is 
less than half (15 vs 30%) in the general population, 
more commonly in men with late-onset MG, and with 
higher administered doses of corticosteroids [18]. 
The increased frequency of neoplasms in MG 
and other autoimmune diseases has long been 
detected. In older studies, the risk for neoplasms in 
MG is three times higher than expected and with a 
higher frequency of occurrence in the first year after 
diagnosis and before thymectomy. After surgery, the 
risk is reduced and is similar to that of the general 
population [43]. 
According to recent reports, the risk of an 
extrathymic tumour is higher in MG with thymoma [44] 
[45] [46], and reported prevalence rate is between 3 
and 12% [46] [47] [48]. 
The nature and origin of tumours are different. 
According to some reports, solid tumours are most 
common, according to others, autoimmune diseases 
treated with immunosuppressive therapy are 
associated more often with the tumour of 
hematopoietic organs and skin [17] [47] [50]. 
The increased risk is explained by 1. the role 
of immune mechanisms in MG in the appearance of 
extrathymic tumours, especially after the diagnosis of 
MG, as a result of impaired immune response and 
immunosuppressive therapy; 2. common genetic 
predisposition to thymomas and other tumours; 3. 
exogenous factors [50]. 
According to the results of our analysis, 
majority of the malignancies have been diagnosed 
before MG and patients were not treated with 
immunosuppressive therapy for MG, the histological 
type, the late onset of the disease, disagree with 
those in studies in which the onset of malignancy is 
more common after the diagnosis of MG [49]. 
Patients with late-onset MG have an 
increased risk of malignant disease; have a more 
severe form of MG, probably due to the weakness and 
dysregulation of the immune system [47]. 
The role of thymectomy as a therapeutic 
modality in MG in the onset of associated autoimmune 
disease has not yet been fully clarified. 
The thymectomy alone does not seem to 
affect the development of associated AD, but it can 
cause a decrease in tolerance to its antigens and be a 
risk factor for its occurrence through the lack of thymic 
hormones that cause disruption of the function of 
suppressor cells, and their substitution can lead to a 
partial return to their function. Experimental studies of 
the SLE model do not show either clinical or changes 
in antibody concentrations, so that thymectomy may 
not be the precipitating factor for the development of 
associated AD [17] [28] [29] [30] [32]. Studies in which 
the occurrence of the associated AD is before MG and 
thymectomy, explain it with the pathogenic effect of 
myasthenic thymus [31]. 
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Only in one patient in this study, the 
associated AD occurs after the thymectomy, which 
supports the consideration of genetic predisposition to 
autoimmune diseases. 
In conclusion, the significance of this study is 
that this research has been done for the first time in 
Macedonia. By using our materials, we have 
researched the occurrence and prevalence of other 
diseases in patients with MG. The results are mainly 
in line with the overall prevalence of all associated 
autoimmune diseases, and the most common 
autoimmune diseases of the thyroid gland are 12.6 %, 
but the rates of SLE, RA, thrombocytopenia, vasculitis 
are lower. 
From the other associated diseases, the most 
frequent one is hypertensive disease; diabetes is in 
line with the published rates, and the least 
represented are dyslipidemia and respiratory 
diseases. The frequency of tumours of extrathymic 
origin is equal to the referenced publications but 
before the diagnosis of MG. The origins, character 
and severity of the conditions, which can occur with 
MG (before or after), impose the need to consider 
their influence on the clinical manifestation and 
treatment of the disease. 
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